74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Anavex Life Sciences Corp
Closed
SectorHealthcare
9.37 0.64
Overview
Share price change
24h
Min
9.24
Max
9.54
Income | -491K -12M |
|---|---|
EPS | -0.14 |
Employees | 42 |
EBITDA | -1.8M -14M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +201.59% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | 745M |
|---|---|
Previous open | 8.73 |
Previous close | 9.37 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Anavex Life Sciences Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Anavex Life Sciences Corp Forecast
Price Target
By TipRanks
201.59% upside
12 Months Forecast
Average 28.5 USD 201.59%
High 42 USD
Low 15 USD
Based on 2 Wall Street analysts offering 12 month price targets forAnavex Life Sciences Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Interest expense on debt
EBITDA
Operating profit
$
About Anavex Life Sciences Corp
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
